Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Evolus, Inc. EOLS
$7.14 -7.15% Close, Oct 2, 2026 · NASDAQ · Market cap $470.2M
Strong growth
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -7.3% from -15.5% a year earlier.
- The stock is in an uptrend: above its 200-day average for 44 trading days, with the 50-day average above the 200-day.
- Revenue over the last four quarters was $316.5M, up 13.9% from a year earlier, accelerating from 9.6% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 41%
- Revenue growth, 3-year CAGRTop 25%
- Revenue growth accelerationTop 19%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 46%
- Gross marginTop 48%
- Operating marginBottom 50%
- Accruals (lower is better)Top 44%
- Interest coverTop 49%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 48%
- Free-cash-flow yieldTop 49%
- EBITDA / enterprise valueTop 42%
- Sales / enterprise valueTop 24%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 35%
- 6-month returnTop 13%
- 1-year return vs S&P 500Top 47%
- Distance from 52-week highTop 37%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 15%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 36%
- Upside to consensus price targetTop 25%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 36%
- Maximum drawdown, 3 yearsBottom 38%
- Beta vs S&P 500 (lower is better)Top 39%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 9.6% | 13.9% | ↑ |
| Gross margin | 66.6% | 66.2% | ↓ |
| Operating margin | -15.5% | -7.3% | ↑ |
| FCF margin | -17.4% | -6.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 13.9% | 9.6% | ↑ | Top 41% |
| Gross margin | 66.2% | 66.6% | ↓ | Top 48% |
| Operating margin | -7.3% | -15.5% | ↑ | Bottom 50% |
| Net margin | -10.8% | -22.3% | ↑ | — |
| Free-cash-flow margin | -6.4% | -17.4% | ↑ | — |
| Return on invested capital | -15.3% | — | Top 46% | |
| Revenue growth, 3-year CAGR | 26.0% | — | Top 25% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +16.9 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.08%
- Shareholder yield
- -0.08%
- Share count change, 1 year
- +2.2%
- Share count change, 3-year CAGR
- +5.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +37.7%
- Average 2-day reaction, last 8
- +1.2%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $18.40
- Target vs current price
- +157.7%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 85%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +122.3% | +1.0% | +36.3% | +48.4% | — |
| May 4, 2026 | +28.6% | +4.7% | +19.3% | +22.3% | +13.1% |
| Mar 3, 2026 | -26.3% | -3.7% | +24.7% | -8.2% | +44.1% |
| Nov 5, 2025 | +26.3% | +6.2% | +9.0% | +5.3% | -23.4% |
| Aug 5, 2025 | -166.7% | -2.2% | -36.7% | -17.7% | -22.7% |
| May 7, 2025 | -80.0% | +1.3% | -12.7% | -15.6% | -21.2% |
| Mar 4, 2025 | -50.0% | +0.1% | -11.6% | -16.1% | -35.1% |
| Nov 6, 2024 | -137.5% | +1.9% | -24.6% | -21.4% | -21.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $0.01 | -$0.03 | +122.3% | $84.1M |
| May 4, 2026 | -$0.10 | -$0.14 | +28.6% | $73.1M |
| Mar 3, 2026 | $0.04 | $0.06 | -26.3% | $90.3M |
| Nov 5, 2025 | -$0.14 | -$0.19 | +26.3% | $69.0M |
| Aug 5, 2025 | -$0.24 | -$0.09 | -166.7% | $69.4M |
| May 7, 2025 | -$0.18 | -$0.10 | -80.0% | $68.1M |
| Mar 4, 2025 | $0.01 | $0.02 | -50.0% | $78.9M |
| Nov 6, 2024 | -$0.19 | -$0.08 | -137.5% | $61.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 1.86× | — | — | Top 24% |
| Free-cash-flow yield | -4.29% | — | — | Top 49% |
| Earnings yield | -7.25% | — | — | Top 48% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 44
- 50-day average slope (20 days)
- +8.7%
- 200-day average slope (20 days)
- +1.9%
- Distance from 50-day average
- -9.1%
- Distance from 200-day average
- +15.9%
- RSI (14)
- 32.6
- Relative volume
- 2.81×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 63.5%
- Volatility vs own 5-year history
- 62th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.95
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- -23.2%
- Maximum drawdown, 3 years
- -77.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 13, 2024 | Mar 30, 2026 | -77.5% | 385 days | Not yet recovered |
| Mar 24, 2021 | Jan 18, 2022 | -68.4% | 207 days | 667 days (Sep 13, 2024) |
| Oct 8, 2020 | Oct 29, 2020 | -39.7% | 15 days | 50 days (Jan 12, 2021) |
| Mar 2, 2021 | Mar 8, 2021 | -20.2% | 4 days | 10 days (Mar 22, 2021) |
| Feb 19, 2021 | Feb 23, 2021 | -19.8% | 2 days | 4 days (Mar 1, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $470.2M
- EPS, diluted (TTM)
- -$0.52
- Revenue (TTM)
- $316.5M
- 52-week range
- $3.86 – $9.31
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Gross profit | $56.1M | $89.8M | $140.5M | $182.3M | $192.8M |
| Operating income | -$44.4M | -$65.3M | -$49.2M | -$34.4M | -$37.6M |
| Net income | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
| EPS (diluted) | -$0.94 | -$1.33 | -$1.08 | -$0.81 | -$0.80 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $61.1M | $78.9M | $68.5M | $69.4M | $69.0M | $90.3M | $73.1M | $84.1M |
| Net income | -$19.2M | -$6.8M | -$18.9M | -$17.1M | -$15.7M | $130,000 | -$10.7M | -$8.1M |
| EPS (diluted) | -$0.30 | -$0.11 | -$0.30 | -$0.27 | -$0.24 | $0.00 | -$0.16 | -$0.12 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$33.4M | -$84.9M | -$34.0M | -$18.0M | -$42.3M |
| Capital expenditure | -$970,000 | -$2.9M | -$1.6M | -$1.5M | -$8.5M |
| Free cash flow | -$34.4M | -$87.9M | -$35.6M | -$19.5M | -$50.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $103.3M | $0 | $0 | $51.2M | $1.2M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $45.2M
- Total assets
- $248.0M
- Total liabilities
- $278.9M
- Total debt
- $164.8M
- Net debt
- $119.6M
- Shareholders’ equity
- -$30.9M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 5,530,759
- Days to cover
- 6.60
- Change vs previous report
- +3.0%
FINRA short interest, settlement date Sep 15, 2026.